Shots:
- AbbVie & Xilio have entered into a collaboration & option-to-license agreement to leverage Xilio’s proprietary tech for developing tumor-activated Abs
- As per the deal, Xilio will get $52M upfront (incl. $10M equity investment), & is entitled to receive ~$2.1B in contingent payments for option-related fees, milestones, & tiered royalties
- Xilio’s platform develops tumor-activated biologics, incl. masked multi-specific immunotherapies for targeted activity within the tumor microenvironment while minimizing systemic adverse effects
Ref: AbbVie | Image: AbbVie & Xilio
Related News:- Abbvie Reports the US FDA Approval for Emblaveo to Treat Complicated Intra-Abdominal Infections (cIAI)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
